Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRAF p.V600K status confers therapeutic sensitivity to Vemurafenib in patients with Melanoma.
The Republic of Ireland's Health Service Executive (HSE) has approved vemurafenib for reimbursement as a monotherapy treatment option for the treatment of adult patients with unresectable or metastatic melanoma whose tumors are BRAF V600 positive.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.